Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nurix Therapeutics Inc NRIX

Healthcare Biotechnology
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug... see more

Recent & Breaking News (NDAQ:NRIX)

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

GlobeNewswire May 28, 2024

Nurix Therapeutics Announces Board Chair Transition

GlobeNewswire May 20, 2024

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

GlobeNewswire May 14, 2024

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 7, 2024

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire April 16, 2024

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

GlobeNewswire April 11, 2024

Nurix Therapeutics Announces Proposed Public Offering

GlobeNewswire April 11, 2024

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

GlobeNewswire April 10, 2024

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

GlobeNewswire April 9, 2024

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

GlobeNewswire April 9, 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire April 3, 2024

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

GlobeNewswire April 2, 2024

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

GlobeNewswire March 25, 2024

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

GlobeNewswire March 20, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

GlobeNewswire March 11, 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire March 6, 2024

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

GlobeNewswire March 5, 2024

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

GlobeNewswire February 15, 2024

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

GlobeNewswire February 1, 2024